| Dr Sief S Naser, MD | |
|
2767 Olive Hwy, Oroville, CA 95966-6118 | |
| (530) 533-8500 | |
| (530) 538-3117 |
| Full Name | Dr Sief S Naser |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 2767 Olive Hwy, Oroville, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598078396 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | R72315 (Arizona) | Secondary |
| 207P00000X | Emergency Medicine | A124264 (California) | Primary |
| Entity Name | Oroville Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235281759 PECOS PAC ID: 1254234339 Enrollment ID: O20040322000325 |
News Archive
A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.
The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.
"The Child Survival Call to Action that took place recently in Washington, D.C., was a unique opportunity for 700 stakeholders working in the government, the private sector, faith-based organizations, and civil society to come together to kick off a long-term, focused effort to save children's lives," Rachel Wilson, the senior director of policy and advocacy at PATH, writes in this post in the Global Health Technologies Coalition's "Breakthroughs" blog.
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.
Long wait times have been a persistent issue for families waiting to see an autism specialist, with waits often exceeding a year.
› Verified 3 days ago
| Entity Name | Orohealth Corporation A Non Profit Healthcare System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013933167 PECOS PAC ID: 4082501192 Enrollment ID: O20040325001703 |
News Archive
A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.
The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.
"The Child Survival Call to Action that took place recently in Washington, D.C., was a unique opportunity for 700 stakeholders working in the government, the private sector, faith-based organizations, and civil society to come together to kick off a long-term, focused effort to save children's lives," Rachel Wilson, the senior director of policy and advocacy at PATH, writes in this post in the Global Health Technologies Coalition's "Breakthroughs" blog.
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.
Long wait times have been a persistent issue for families waiting to see an autism specialist, with waits often exceeding a year.
› Verified 3 days ago
| Entity Name | Solano Gateway Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952344293 PECOS PAC ID: 5496725418 Enrollment ID: O20040916001355 |
News Archive
A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.
The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.
"The Child Survival Call to Action that took place recently in Washington, D.C., was a unique opportunity for 700 stakeholders working in the government, the private sector, faith-based organizations, and civil society to come together to kick off a long-term, focused effort to save children's lives," Rachel Wilson, the senior director of policy and advocacy at PATH, writes in this post in the Global Health Technologies Coalition's "Breakthroughs" blog.
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.
Long wait times have been a persistent issue for families waiting to see an autism specialist, with waits often exceeding a year.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sief S Naser, MD 2767 Olive Hwy, Oroville, CA 95966-6118 Ph: (530) 533-8500 | Dr Sief S Naser, MD 2767 Olive Hwy, Oroville, CA 95966-6118 Ph: (530) 533-8500 |
News Archive
A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.
The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.
"The Child Survival Call to Action that took place recently in Washington, D.C., was a unique opportunity for 700 stakeholders working in the government, the private sector, faith-based organizations, and civil society to come together to kick off a long-term, focused effort to save children's lives," Rachel Wilson, the senior director of policy and advocacy at PATH, writes in this post in the Global Health Technologies Coalition's "Breakthroughs" blog.
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.
Long wait times have been a persistent issue for families waiting to see an autism specialist, with waits often exceeding a year.
› Verified 3 days ago
Micaela A Assam, FNP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2145 5th Ave, Oroville, CA 95965 Phone: 530-534-5394 | |
David Hobart Hall, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2767 Olive Highway, Oroville, CA 95966 Phone: 530-532-8584 Fax: 530-532-8433 | |
Cynthia Cellucci-chwalik, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2767 Olive Hwy, Oroville, CA 95966 Phone: 530-533-8500 | |
Oday Naser, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2767 Olive Hwy, Oroville, CA 95966 Phone: 530-533-8500 | |
Peter Martin Russo, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1611 Feather River Blvd, Suite #10, Oroville, CA 95965 Phone: 530-534-4530 Fax: 530-532-8290 | |
Douglas James Fischer, NP Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2767 Olive Hwy, Oroville, CA 95966 Phone: 530-532-8347 |